Stratipath Breast analyses digital images of tumour tissue to assess the risk of breast cancer recurrence. The results are intended to provide doctors with additional information when deciding whether to give chemotherapy after surgery.
The new recommendation applies to the use of Stratipath Breast to inform treatment decisions for patients with ER-positive, HER2-negative breast cancer of histological grade 2, also known as NHG2.
AdvertisementFor some of these patients, it can be difficult to determine whether they need additional treatment. According to the council, the need for further decision support is particularly great when the tumour is small, has not spread to the lymph nodes and its characteristics make the choice of treatment less clear.
In such cases, gene expression tests, including Prosigna, are among the methods currently used to assess the risk of recurrence. Stratipath Breast has been identified as a potential way to reduce the need for these tests and make the assessment faster and less costly.
Disagreement over the evidence
At the council’s request, Sweden’s Dental and Pharmaceutical Benefits Agency (TLV) carried out a health economic assessment of Stratipath Breast. The agency concluded that the scientific evidence was uncertain and that it was not possible to determine whether the tool was better, worse or comparable to the Prosigna gene expression test at predicting outcomes for the patient group in question.
AdvertisementAgainst this background, the council is recommending that regions refrain from using the tool to inform decisions on additional treatment for patients with grade 2 tumours.
“There is both considerable interest in and potential for AI-based methods that can contribute to more efficient cancer care. For Stratipath Breast, the council considers that more knowledge is needed about how well the method works for the patient group with the greatest need for additional decision support. On this basis, the method cannot currently be recommended for this patient group,” said Annkristin Svensbergh, chair of the Medical Technology Product Council, in a press release.
Stratipath disagrees with the assessment. In a written response to Life Science Focus, the company said it had challenged the council’s assessment and requested a meeting to review the evidence.
Advertisement“We do not think the assessment is accurate at all, and it risks slowing Swedish patients’ access to new, more effective solutions,” wrote Lars Lengquist, head of communications at Stratipath.
Stratipath has submitted results from the validation of the tool in the TAILORx clinical breast cancer study, as well as results from three studies due to be presented at the San Antonio Breast Cancer Symposium in December. According to the company, these are not cited in the assessment.
The company also argues that Stratipath Breast is being assessed on different grounds from the gene expression tests used for the same patient group. Stratipath points out that the product has been used by Swedish regions for several years and has been validated in more than 10,000 patients.
AdvertisementNew study results expected
According to Stratipath, the three studies due to be presented in December include a large Swedish patient cohort, a US clinical cohort and a health economic analysis. A publication from the TAILORx validation is also expected in 2027.
The council said Stratipath Breast could be used in clinical studies. It may also reconsider its recommendation if new studies provide further evidence of the method’s clinical benefit.
Stratipath was founded in 2019 as a spin-out from research at Karolinska Institutet. Stratipath Breast received CE marking as a class C device under the EU’s In Vitro Diagnostic Regulation (IVDR) in June this year.
Stratipath recently entered into a partnership with Roche concerning distribution rights for Stratipath Breast.
Advertisement